TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation

Area of Science:

• Molecular Biology
• Immunology
• Hepatology

Background:

• Tristetraprolin (TTP) is an immunosuppressive protein regulating mRNA decay via AU-rich elements (AREs).
• The role of TTP in liver disease pathogenesis is established, but its mechanisms beyond ARE recognition are unclear.
• Acute liver failure (ALF) involves complex molecular dysregulation impacting hepatic function.

Purpose of the Study:

• To investigate the role of TTP in mRNA stability regulation beyond AREs in the context of ALF.
• To elucidate the specific mechanisms by which TTP influences mRNA stability in ALF.
• To explore the therapeutic potential of TTP modulation in ALF.

Main Methods:

• Analysis of TTP expression levels in ALF models.
• Assessment of CCL2 and CCL5 mRNA stability and N6-methyladenosine (m6A) methylation.
• In vivo studies involving TTP overexpression to evaluate hepatic injury.
• Examination of the expression of m6A-modulating enzymes.

Main Results:

• TTP was upregulated in ALF, correlating with decreased CCL2 and CCL5 mRNA stability.
• TTP promoted m6A methylation of CCL2 and CCL5 mRNAs, leading to their destabilization.
• Overexpression of TTP ameliorated hepatic injury in vivo.
• TTP induction upregulated key m6A methyltransferases, increasing global m6A levels.

Conclusions:

• TTP modulates CCL2 and CCL5 mRNA stability through a novel mechanism involving m6A RNA methylation.
• This TTP-mediated m6A pathway plays a significant role in ALF pathogenesis.
• Targeting TTP-induced m6A modification represents a potential therapeutic strategy for ALF.